★★★★★
The whole process from placing the order to receiving the package was quite straightforward, and I appreciated how the items were handled carefully, giving a sense of professionalism and attention to detail throughout.
CBL514
CBL-514 (20 mg)
CBL-514 is an investigational small-molecule lipolysis drug candidate, with reported DYRK1B-inhibitory activity. Each box contains 10 vials, with 20 mg per vial. For qualified laboratory research only.
Testing coming soon from Janoshik.
No batch-specific certificate of analysis (COA) is currently available. View testing status.
$600.00AUD / box of 10
Free shipping on all products.
Research Use Only
For use by qualified professionals in controlled laboratory research. Not for human consumption, therapeutic use or veterinary use.
Testing coming soon from Janoshik
Testing documentation for batch EP-250407-CBL514 is not available yet. A Janoshik COA will be published here when it has been received and reviewed.
What is CBL-514?
CBL-514 is an investigational small-molecule lipolysis drug candidate. Its reported mechanism involves DYRK1B inhibition and adipocyte apoptosis, the programmed death of fat cells. [1]
DYRK1B inhibition and adipocyte apoptosis
The 2022 Phase 2a paper describes inhibition of the cell-survival kinase DYRK1B, increased caspase-3 expression and a higher Bax/Bcl-2 ratio in the sponsor's nonclinical studies. These findings describe the proposed mechanism; they are not direct evidence of target engagement in humans. [1]
Conditions and applications under development
- Localised subcutaneous fat reduction: clinical studies assess fat volume and thickness in targeted areas, including the abdomen. [2]
- Dercum's disease (adiposis dolorosa): a published Phase 2a study examined lipoma volume and pain in this disorder of painful fatty growths. These are two names for the same condition. [3]
- Cellulite: The study sponsor has reported Phase 2 results from its CBL-0201EFP programme. [4]
- Obesity and weight management: the sponsor has announced a Phase 2 development programme evaluating CBL-514 alongside a GLP-1/GIP receptor agonist in people with obesity or overweight. This is an investigational application. [5]
Clinical programmes may use different formulations. The study sponsor distinguishes CBL-514D, a formulation with the same active ingredients under development for Dercum's disease. Study results describe the specific formulation and conditions investigated. [5]
Product documentation: Published clinical findings do not establish the identity, quality, safety or effectiveness of this separately supplied product. Clinical equivalence is not claimed; see the batch-specific testing information above.